Company intelligence / Profile preview

KA Imaging

Waterloo, Ontario, Canadakaimaging.com ↗

Ownership: Private
Development stage: Other

Overview

KA Imaging’s SpectralDR™ technology enables single-exposure dual-energy subtraction X-ray imaging, providing simultaneous conventional and spectral images. Clinical studies have shown improved image quality, increased diagnostic confidence for pneumonia and pulmonary conditions in ICU settings, and a reduction in unnecessary CT scans. The Reveal Mobi Pro system has received CE Mark approval for sale in Europe.

Therapeutic areas: PulmonologyOncologyInfectious DiseasesOther
Modalities: DeviceDigital X-ray detectorDual-energy subtraction imaging technology (SpectralDR™)
Industry: Medical Imaging

Partnerships

Collaborations with University Health Network/UHN via OBIO EAHN program for clinical validation of the technology in immunocompromised/cancer patients.

Beyond the preview

Go deeper on KA Imaging.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KA Imaging.

Explore the full profile